Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:651757.
doi: 10.1155/2015/651757. Epub 2015 Aug 20.

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

Affiliations
Review

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

XingChun Wang et al. Int J Endocrinol. 2015.

Abstract

The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels. It also improves beta-cell proliferation and prevents beta-cell apoptosis induced by cytotoxic agents. Additionally, glucagon-like peptide-1 delays gastric emptying and suppresses appetite. The impaired secretion of glucagon-like peptide-1 has negative influence on diabetes, hyperlipidemia, and insulin resistance related diseases. Thus, glucagon-like peptide-1-based therapies (glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) are now well accepted in the management of type 2 diabetes. The levels of glucagon-like peptide-1 are influenced by multiple factors including a variety of nutrients. The component of a meal acts as potent stimulants of glucagon-like peptide-1 secretion. The levels of its secretion change with the intake of different nutrients. Some drugs also have influence on GLP-1 secretion. Bariatric surgery may improve metabolism through the action on GLP-1 levels. In recent years, there has been a great interest in developing effective methods to regulate glucagon-like peptide-1 secretion. This review summarizes the literature on glucagon-like peptide-1 and related factors affecting its levels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levels of glucagon-like peptide-1 related factors.

Similar articles

Cited by

References

    1. Lund A., Knop F. K., Vilsbøll T. Emerging GLP-1 receptor agonists. Expert Opinion on Emerging Drugs. 2011;16(4):607–618. doi: 10.1517/14728214.2011.616493. - DOI - PubMed
    1. Drucker D. J., Nauck M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006;368(9548):1696–1705. doi: 10.1016/s0140-6736(06)69705-5. - DOI - PubMed
    1. Doyle M. E., Egan J. M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & Therapeutics. 2007;113(3):546–593. doi: 10.1016/j.pharmthera.2006.11.007. - DOI - PMC - PubMed
    1. Holst J. J. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87(4):1409–1439. doi: 10.1152/physrev.00034.2006. - DOI - PubMed
    1. Gil-Lozano M., Mingomataj E. L., Wu W. K., Ridout S. A., Brubaker P. L. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell. Diabetes. 2014;63(11):3674–3685. doi: 10.2337/db13-1501. - DOI - PubMed

LinkOut - more resources